Healiva® Company Profile

Background

Overview

Healiva® is a patient-centric Swiss biotech company founded in 2020, dedicated to developing personalized and affordable therapies for chronic wound care. By integrating cell therapies, enzyme technology, and medical devices, Healiva® aims to address the significant unmet needs in wound healing, offering comprehensive solutions that enhance patients' quality of life.

Mission and Vision

Healiva®'s mission is to heal life by delivering innovative, personalized, and affordable therapies for chronic wounds. The company envisions transforming wound care by bridging the gap in current treatment paradigms, particularly for non-healing wounds, and providing patients with effective, accessible solutions.

Primary Area of Focus

Healiva® specializes in the development of personalized cell therapies, enzyme-based treatments, and medical devices aimed at chronic wound care. The company's focus encompasses acute and chronic wounds, including venous leg ulcers and diabetic foot ulcers, addressing the complexities of wound healing through a multifaceted approach.

Industry Significance

The chronic wound care market is substantial, with an estimated 156 million patients worldwide. Conditions such as venous leg ulcers and diabetic foot ulcers are prevalent, leading to significant healthcare burdens. Healiva®'s innovative solutions position the company as a key player in addressing these challenges, offering personalized and effective treatments that aim to improve patient outcomes and reduce healthcare costs.

Key Strategic Focus

Core Objectives

Healiva® aims to develop a comprehensive portfolio of personalized therapies for chronic wounds, focusing on:

• Personalization: Tailoring treatments to individual patient needs to enhance healing outcomes.

• Affordability: Ensuring that advanced wound care solutions are accessible to a broad patient population.

• Innovation: Integrating cutting-edge technologies to address the complexities of chronic wound healing.

Specific Areas of Specialization

The company's specialization includes:

• Cell Therapies: Utilizing autologous and allogeneic cell-based treatments to promote tissue regeneration.

• Enzyme Technology: Developing enzymatic debriding agents for painless and effective wound cleaning.

• Medical Devices: Creating devices that support wound healing processes and improve patient care.

Key Technologies Utilized

Healiva® employs several innovative technologies, such as:

• Autologous Epidermal Equivalents: Creating personalized skin grafts from patients' own cells to treat severe chronic wounds.

• Enzymatic Debriding Agents: Developing agents that facilitate painless and efficient wound cleaning.

• Cell Sprays: Utilizing allogeneic cell sprays to stimulate growth factors and accelerate healing.

Primary Markets Targeted

Healiva® primarily targets:

• Healthcare Providers: Hospitals and clinics requiring advanced wound care solutions.

• Patients: Individuals suffering from chronic wounds, including those with diabetes and vascular diseases.

• Insurance Providers: Organizations seeking cost-effective wound care treatments to reduce long-term expenses.

Financials and Funding

Funding History

Healiva® has secured funding through various channels, including:

• Seed Funding: In November 2021, Healiva® raised an undisclosed amount in a seed funding round.

• Grants and Accelerators: The company has participated in programs such as MassChallenge, receiving support to advance its innovations.

Total Funds Raised

The exact total funds raised by Healiva® are not publicly disclosed.

Notable Investors

Healiva®'s investors include:

• MassChallenge: An accelerator program that supports early-stage startups.

Utilization of Capital

The capital raised is intended for:

• Product Development: Advancing the clinical and commercial development of Healiva®'s wound care solutions.

• Regulatory Approvals: Obtaining necessary certifications and approvals for market entry.

• Operational Expansion: Scaling manufacturing capabilities and expanding the company's operational infrastructure.

Pipeline Development

Key Pipeline Candidates

Healiva® is developing several pipeline candidates, including:

• EpiDex®: An autologous epidermal equivalent for treating severe chronic venous leg ulcers.

• Healiva 003 (AQUAtyrp): An enzymatic debriding agent designed for painless wound cleaning and preparation.

• Healiva 002: An allogeneic cell spray aimed at stimulating growth factors to accelerate wound healing.

• Healiva 004: An autologous blood patch prepared at the point of care for wound treatment.

Stages of Development

The pipeline candidates are at various stages, including:

• Pre-clinical Development: Ongoing research and development to optimize formulations and manufacturing processes.

• Clinical Trials: Plans to initiate clinical trials upon completion of pre-clinical studies and regulatory approvals.

Target Conditions

The primary target conditions for these therapies are:

• Venous Leg Ulcers (VLUs): Chronic wounds resulting from impaired venous circulation.

• Diabetic Foot Ulcers (DFUs): Chronic wounds commonly caused by diabetes-related complications.